IKK antagonizes activation-induced cell death of CD4 + T cells in aged mice via inhibition of JNK activation

T cell dysfunction is the primary immunologic abnormality associated with aging. Many age-related defects stem from a decline in CD4 + T cell function. Resistance of aged CD4 + T cells to apoptosis is associated with autoimmune and infectious diseases. Previous studies suggest that IκB kinase (IKK)...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Molecular immunology 2010-11, Vol.48 (1-3), p.287-293
Hauptverfasser: Deng, Hongbin, Mao, Genxiang, Zhang, Jingpu, Wang, Zhen, Li, Diandong
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:T cell dysfunction is the primary immunologic abnormality associated with aging. Many age-related defects stem from a decline in CD4 + T cell function. Resistance of aged CD4 + T cells to apoptosis is associated with autoimmune and infectious diseases. Previous studies suggest that IκB kinase (IKK) may be a key player in cell survival via its inhibition of c-Jun N-terminal protein kinase (JNK) activation. However, the role of IKK-mediated JNK inactivation in the age-related apoptosis of T cells is unclear. Here, we report that splenic CD4 + T cells in aged mice are resistant to activation-induced cell death (AICD) induced by anti-CD3 plus IL-2 stimulation. Furthermore, aged CD4 + T cells display increased IKKβ activity that is associated with attenuated JNK activation. The IKKβ-mediated JNK inactivation in aged CD4 + T cells reduces the degradation of c-FLIP L and the interaction of Bad with Bcl-X L, but it increases the affinity of Bad for 14-3-3. Pretreatment of aged CD4 + T cells with a specific IKK inhibitor, PS1145, increases the JNK activity blocked by IKKβ and consequently sensitizes the aged CD4 + T cells to AICD. Our study thus demonstrates that IKK antagonizes the AICD of CD4 + T cells in aged mice via inhibition of JNK activation.
ISSN:0161-5890
1872-9142
DOI:10.1016/j.molimm.2010.07.015